These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 2521224

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A phase I trial of CGS 16949A. A new aromatase inhibitor.
    Lipton A, Harvey HA, Demers LM, Hanagan JR, Mulagha MT, Kochak GM, Fitzsimmons S, Sanders SI, Santen RJ.
    Cancer; 1990 Mar 15; 65(6):1279-85. PubMed ID: 2137721
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Preliminary study of the treatment of advanced breast cancer in postmenopausal women with the aromatase inhibitor CGS 16949A.
    Stein RC, Dowsett M, Davenport J, Hedley A, Ford HT, Gazet JC, Coombes RC.
    Cancer Res; 1990 Mar 01; 50(5):1381-4. PubMed ID: 2137367
    [Abstract] [Full Text] [Related]

  • 8. In vitro and in vivo studies demonstrating potent and selective estrogen inhibition with the nonsteroidal aromatase inhibitor CGS 16949A.
    Steele RE, Mellor LB, Sawyer WK, Wasvary JM, Browne LJ.
    Steroids; 1987 Mar 01; 50(1-3):147-61. PubMed ID: 2973160
    [Abstract] [Full Text] [Related]

  • 9. Effect of aromatase inhibitors on estrogen 2-hydroxylase in rat liver.
    Purba HS, King EJ, Richert P, Bhatnagar AS.
    J Steroid Biochem Mol Biol; 1994 Feb 01; 48(2-3):215-9. PubMed ID: 8142297
    [Abstract] [Full Text] [Related]

  • 10. Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients.
    Demers LM.
    Breast Cancer Res Treat; 1994 Feb 01; 30(1):95-102. PubMed ID: 7949208
    [Abstract] [Full Text] [Related]

  • 11. Recent progress in development of aromatase inhibitors.
    Santen RJ.
    J Steroid Biochem Mol Biol; 1990 Dec 20; 37(6):1029-35. PubMed ID: 2149503
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Potency and specificity of CGS-16949A as an aromatase inhibitor.
    Santen RJ, Langecker P, Santner SJ, Sikka S, Rajfer J, Swerdloff R.
    Endocr Res; 1990 Dec 20; 16(1):77-91. PubMed ID: 2139412
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Antitumor effects of a nonsteroidal aromatase inhibitor (CGS 16949A) on 7, 12-dimethylbenz[alpha]anthracene-induced mammary tumors in rats.
    Iino Y, Sugamata N, Owada S, Tago T, Sato H, Yokoe T, Maemura M, Morishita Y, Horiuchi R.
    Jpn J Clin Oncol; 1991 Jun 20; 21(3):153-9. PubMed ID: 1834875
    [Abstract] [Full Text] [Related]

  • 20. An in vitro method to determine the selective inhibition of estrogen biosynthesis by aromatase inhibitors.
    Häusler A, Schenkel L, Krähenbühl C, Monnet G, Bhatnagar AS.
    J Steroid Biochem; 1989 Jul 20; 33(1):125-31. PubMed ID: 2527324
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.